SCHEMBL4834707

SCHEMBL4834707

CC(=O)C(O)[C@H]1O[C@@H](n2cnc3c(Cl)ncnc32)[C@@](O)(C(C)=O)[C@@]1(O)C(C)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
ADORA3 P0DMS8 8/20 0.36
ADORA2A P29274 5/20 0.36
P2RX7 Q99572 1/20 0.35
FDPS P14324 1/20 0.34
TYMP P19971 1/20 0.34
ADORA1 P30542 4/20 0.33
FGFR1 P11362 4/20 0.33
FGFR4 P22455 4/20 0.33
TSHR P16473 1/20 0.33
LMNA P02545 1/20 0.33
THRB P10828 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90B1 P14625 1/20 0.33
AHCY P23526 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6386486 1.00 PDE4A (0.37) PDE4APDE4BPDE4CPDE4DADORA3
SCHEMBL4833723 0.88 ADORA3 (0.37) ADORA3ADORA2AADORA1TSHRLMNA
SCHEMBL30544925 0.88 ADORA2A (0.49) ADORA3ADORA2AADORA1TSHRLMNA
SCHEMBL4948918 0.87 LMNA (0.43) ADORA3ADORA2AADORA1LMNAADORA2B
SCHEMBL6909391 0.86 NPEPPS (0.39) LMNA
SCHEMBL5498228 0.86 LMNA (0.37) ADORA3ADORA2AADORA1LMNAADORA2B
SCHEMBL5492971 0.86 NT5E (0.38) ADORA3ADORA2AADORA1LMNAHSP90B1
SCHEMBL9404373 0.85 LMNA (0.35) ADORA3ADORA2AADORA1LMNAAHCY
SCHEMBL5735963 0.85 LMNA (0.35) ADORA3ADORA2AADORA1LMNA
SCHEMBL7068201 0.84 ADORA2A (0.35) PDE4APDE4BPDE4CPDE4DADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345164-B2 Production method of 5′-acyloxynucleoside compound AJINOMOTO CO., INC. (JP) 2008-03-18 US disclosed
US-20060014944-A1 Processes for production of nucleosides AJINOMOTO CO., INC. (JP) 2006-01-19 US disclosed
EP-1589027-A1 PROCESSES FOR PRODUCTION OF NUCLEOSIDES Ajinomoto Co., Inc. (JP) 2005-10-26 EP disclosed
US-20040230053-A1 Production method of 5'-acyloxynucleoside compound AJINOMOTO CO., INC. (JP) 2004-11-18 US disclosed
EP-1471071-A1 Production method of 5'-acyloxynucleoside compound Ajinmoto Co., Inc. (JP) 2004-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014944-A1 Processes for production of nucleosides NUDT1, NT5C3B, DNTT PDE4A 1682/4885PDE4B 1250/4885PDE4C 1245/4885
US-20040230053-A1 Production method of 5'-acyloxynucleoside compound ALKBH2, DUT, ALKBH1 PDE4A 1200/4885PDE4B 868/4885PDE4C 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.